

POLICY NUMBER UM_ONC_1349	SUBJECT Talzenna™ (talazoparib)	DEPT/PROGRAM UM Dept	PAGE 1 OF 2
DATES COMMITTEE REVIEWED 11/14/18, 07/09/19, 12/11/19, 05/13/20	APPROVAL DATE May 13, 2020	EFFECTIVE DATE May 29, 2020	COMMITTEE APPROVAL DATES (latest version listed last) 11/14/18, 07/09/19, 12/11/19, 05/13/20
PRIMARY BUSINESS OWNER: UM APPROVED BY: Dr. Andrew Hertler		COMMITTEE/BOARD APPROVAL Utilization Management Committee	
URAC STANDARDS HUM 1		NCQA STANDARDS UM 2	ADDITIONAL AREAS OF IMPACT
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS	APPLICABLE LINES OF BUSINESS All	

I. PURPOSE

To define and describe the accepted indications for Talzenna (Talazoparib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century is responsible for processing all medication requests from network ordering providers. Medications not authorized by New Century may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

1. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

- When health plan Medicaid coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the **Preferred Drug Guidelines OR**
- When health plan Exchange coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the **Preferred Drug Guidelines OR**
- For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the **Preferred Drug Guidelines shall follow NCH L1 Pathways** when applicable, otherwise shall follow NCH drug policies **AND**
- Continuation requests of previously approved non-preferred medication are not subject to this provision **AND**
- When available, generic alternatives are preferred over brand-name drugs.

2. Breast Cancer

- NOTE #1:** The preferred PARP inhibitor, per NCH policy and NCH pathway, is **OLAPARIB** for recurrent or metastatic, germline BRCA 1/2 mutation positive, and HER2 negative breast cancer. Please refer to the NCH Pathway document for the current recommended regimens.
- NOTE #2:** New data from the phase III EMBRACA trial, reported April 2020, did not show a statistically significant overall survival benefit for patient with metastatic breast cancer with a germline BRCA 1/2 mutation.



New Century Health

Policy #UM_Onc_1349
PROPRIETARY & CONFIDENTIAL

III. EXCLUSION CRITERIA

1. No history of intolerance to/contraindications to Olaparib.
2. Dosing exceeds single dose limit of Talzenna (talazoparib) 1 mg.
3. Treatment exceeds the maximum limit of 120 (0.25 mg) or 30 (1mg) capsules/month.
4. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

IV. MEDICATION MANAGEMENT

Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

1. Review – Utilization Management Department
2. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

None

VII. REFERENCES

1. Talzenna PI prescribing information. Pfizer Laboratories Div NY, NY 2020.
2. Clinical Pharmacology Elsevier Gold Standard. 2020.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2020.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2020.
5. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD. 2020.